Matrixyl (Palmitoyl Pentapeptide-4)
experimentalAlso known as: Palmitoyl pentapeptide-4, Pal-KTTKS, Matrixyl
**Mechanism of Action** Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) functions as a matrikine signal peptide, mimicking the natural collagen degradation fragments that trigger tissue repair. By binding to cell surface receptors on fibroblasts, it upregulates the synthesis of extracellular matrix components, including collagen types I and III, and fibronectin. This signaling cascade promotes dermal remodeling, leading to improved skin firmness and reduced wrinkle depth following topical application. **Key Research Findings** In vitro studies demonstrate that Pal-KTTKS significantly increases procollagen I and fibronectin production in human dermal fibroblasts. Clinical trials (n=93, 12-week split-face design) show a statistically significant reduction in wrinkle volume and depth compared to vehicle control, with visible improvements in periorbital and nasolabial folds. Histological analysis confirms increased collagen density in treated skin. However, most studies are small-scale, industry-funded, and lack long-term safety data beyond 12 weeks. **Clinical Relevance** Matrixyl is widely incorporated into anti-aging cosmeceuticals, though its efficacy is modest compared to retinoids or prescription treatments. It is generally well-tolerated with minimal irritation, making it suitable for sensitive skin. Current evidence supports its use as an adjunctive topical agent for mild-to-moderate photoaging, but robust independent trials are needed to confirm durability of effects and optimal formulation concentrations. For research purposes only — not medical advice.
Key data
C39H75N7O10Research & studies
Both preparation methods yielded homogeneous liposomes with PdI < 0.20 and mean diameters <100 nm (REV) or <200 nm (TLE).; Liposomes had a net negative surface charge and over 90% structured phospholipids.; Pal-KTTKS delivered via PC liposomes stimulated collagen production more than free pentapeptide or 1 mM ascorbic acid.
0.1 μM Pal-KTTKS decreased α-SMA-positive stress fibers per field from 75% to 38.6% (p < 0.05).; The inhibitory effect on myofibroblast differentiation was dose-dependent and not significant at 0.5 μM.; Stress fiber levels and collagen contractility correlated with α-SMA expression.; A delicate balance between wound healing and pro-fibrotic effects of Pal-KTTKS is needed for therapeutic dosing.
Frequently asked questions
What is Matrixyl (Palmitoyl Pentapeptide-4)?
**Mechanism of Action** Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) functions as a matrikine signal peptide, mimicking the natural collagen degradation fragments that trigger tissue repair. By binding to cell surface receptors on fibroblasts, it upregulates the synthesis of extracellular matrix components, including
How does Matrixyl (Palmitoyl Pentapeptide-4) work?
Matrikine signal peptide that stimulates collagen I, III, and fibronectin synthesis to reduce wrinkle depth in topical use.
What is the research status of Matrixyl (Palmitoyl Pentapeptide-4)?
Matrixyl (Palmitoyl Pentapeptide-4) is currently classified as experimental, with 15 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Matrixyl (Palmitoyl Pentapeptide-4)?
Matrixyl (Palmitoyl Pentapeptide-4) has a molecular weight of approximately 802.1 g/mol (formula C39H75N7O10).
Related peptides
SNARE-mimetic hexapeptide that mildly inhibits catecholamine/acetylcholine release to soften expression lines ('topical Botox').
Octapeptide extension of Argireline that competes with SNAP-25 in the SNARE complex to reduce muscle contraction and wrinkles.
Build on Matrixyl (Palmitoyl Pentapeptide-4) data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key